Drug Trial Radar · NCT05408663
A Phase 1 Study of EXT608 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jul 21, 2022
Primary completion
Jun 13, 2023
Study completion Jun 13, 2023
Sponsor
- Lead sponsor
- Extend Biosciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Integrated Medical Development; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Pharmaceutical Research Associates
- First posted
- Jun 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose safety and tolerability study of EXT608 in healthy subjects. There will be up to 6 sequential dose escalation cohorts of 4 participants. In each cohort 3 participants will receive EXT608 and 1 participant will receive placebo.
Conditions
- Safety Issues
Interventions
EXT608Drug
EXT608 is an investigational drug administered via subcutaneous injection
PlaceboOther
matching placebo administered via subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterize the Safety and Tolerability of EXT608Time frame: Day 0 to Day 28
- Characterize the Safety and Tolerability of EXT608Time frame: Day 0 - Day 28
- Characterize the Safety and Tolerability of EXT608Time frame: Day 0 - Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PRA
Lenexa, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.